The Human Variable 

Personalized CRISPR Remission™ for sarcoidosis introduces a state-dependent precision medicine framework integrating immune biology, environmental exposure, safety modeling, and CYNAERA predictive systems to improve durable response and reduce variability.

CYNAERA’s Personalized CRISPR Remission™ in melanoma integrates PD-1 edited TIL therapy, tumor microenvironment alignment, and VitalGuard™ modeling to improve durable response prediction.

A new framework for disease prevalence estimation, the Diagnostic Multiplier™ (DM™) adjusts for underdiagnosis, diagnostic variability, and environmental exposure across conditions.

CRISPR Remission™ for Lyme disease introduces a personalized CRISPR framework integrating environmental burden, immune variability, and state-dependent intervention to address persistent Lyme and post-treatment Lyme disease.

CRISPR Remission™ for CRPS integrates gene editing, environmental triggers, and flare-aware timing to enable durable stabilization in complex regional pain syndrome.

State-dependent oral CRISPR delivery framework modeling uptake, EBV targeting, and gene editing efficiency. Explores how immune state, environmental burden, and physiology determine real-world therapeutic success.